	US 11,685,952 B2
	Biomarker for predicting risk of recurrence in patients with paroxysmal atrial fibrillation
Jong Il Choi, Seoul (KR)
Assigned to KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION, Seoul (KR)
Filed by KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION, Seoul (KR)
Filed on Jul. 14, 2020, as Appl. No. 16/928,828.
Claims priority of application No. 10-2020-0001844 (KR), filed on Jan. 7, 2020.
Prior Publication US 2021/0207216 A1, Jul. 8, 2021
Int. Cl. C12Q 1/68 (2018.01); C12P 19/34 (2006.01); C12Q 1/6883 (2018.01); C12Q 1/37 (2006.01)

CPC C12Q 1/6883 (2013.01) [C12Q 1/37 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/156 (2013.01)]

4 Claims

1. A method of predicting a risk of recurrence of paroxysmal atrial fibrillation (AF) in a patient after treatment of AF, the method comprising following steps:

(1) obtaining a blood sample from the patient;

(2) measuring a concentration of tissue inhibitor of metalloproteinase (TIMP)-1 of 107 ng/ml or greater in the sample;

(3) detecting the presence of a G/T or T/T genotype of the rs10033464 polymorphism in nucleic acid from the sample;

(4) predicting a high risk of recurrence of paroxysmal AF in said patient based on said measured concentration of TIMP-1 of 107 ng/ml or greater and said G/T or T/T genotype at rs10033464; and

(5) treating said patient with an additional treatment for AF, wherein said additional treatment is a pharmacological treatment for AF.